Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Auckland) 2021-01, Vol.12, p.11-20
Hauptverfasser:	Tan, Aaron C, Loh, Tracy J, Kwang, Xue Lin, Tan, Gek San, Lim, Kiat Hon, Tan, Daniel S W
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Binding sites c-Met protein capmatinib Clinical trials Crizotinib Deoxyribonucleic acid DNA Dosage Gene amplification Health aspects Kinases Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell met exon 14 skipping Metastases Metastasis Mutation non-small cell lung cancer Non-small cell lung carcinoma Pharmaceutical industry Protein-tyrosine kinase Proteins Review Small cell lung carcinoma targeted therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.
ISSN:	1179-2728 1179-2728
DOI:	10.2147/LCTT.S263610